Short answer
COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an 8-K current report with the SEC on May 12, 2026 reporting Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). Collegium completed acquisition of AZSTARYS®, an ADHD stimulant for patients aged 6 and older.
COLLEGIUM PHARMACEUTICAL, INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Collegium completed acquisition of AZSTARYS®, an ADHD stimulant for patients aged 6 and older
- $650 million upfront cash consideration, subject to customary closing adjustments
- Funding included $350 million existing cash and $300 million delayed-draw term loan
- Up to $135 million additional consideration tied to future commercial and manufacturing milestones
Item 5.02 · Departure/Election of Directors or Officers
- Chief Commercial Officer Scott Dreyer departing August 30, 2026, treated as termination without cause
- Chief Medical Officer Thomas Smith departing after successor transition, creating commercial and clinical leadership vacancies
- Board adopted inducement plan covering 325,000 common-stock shares for eligible new hires
- Plan enables equity-based recruitment without shareholder approval under Nasdaq Rule 5635(c)(4)
Item 7.01 · Regulation FD Disclosure
- May 12, 2026 press release announced the Closing, signaling completion of a material transaction
- Exhibit 99.1 contains the substantive closing details and is furnished, not filed under Section 18
- Limited liability for the disclosure unless expressly incorporated into future Securities Act or Exchange Act filings
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other COLLEGIUM PHARMACEUTICAL, INC 8-K filings
Get the next COLL 8-K as it lands
Follow COLL for push alerts, or ask the research agent what this filing means.